Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58

Journal of General Virology

Volumn 91, Issue 7, 2010, Pages 1834-1839

  Brendle, Sarah A ^a   Culp, Timothy D ^a   Broutian, Tatevik R ^a,b   Christensen, Neil D ^a,b,c  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALININ; MONOCLONAL ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ARTICLE; EXTRACELLULAR MATRIX; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 58; HYBRIDOMA CELL CULTURE; IMMUNOFLUORESCENCE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; RISK FACTOR; ALPHAPAPILLOMAVIRUS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE; CLASSIFICATION; IMMUNOLOGY;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 58;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE; EPITOPES; HUMANS; IMMUNOGLOBULIN G;

EID: 77954163109     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.017228-0     Document Type: Article

References (32)

1. Bhatla, N., Lal, N., Bao, Y. P., Ng, T. & Qiao, Y. L. (2008). A meta-analysis of human papillomavirus type distribution in women from South Asia: implications for vaccination. Vaccine 26, 2811-2817.
2. Broutian, T. R., Brendle, S. A. & Christensen, N. D. (2010). Differential binding patterns to host cells associated with particles of several human alpha papillomavirus types. J Gen Virol 91, 531-540.
3. Buck, C. B., Thompson, C. D., Pang, Y. Y. S., Lowy, D. R. & Schiller, J. T. (2005). Maturation of papillomavirus capsids. J Virol 79, 2839-2846.
4. Chan, P. K. S., Mak, K. H., Cheung, J. L. K., Tang, N. L. S., Chan, D. P. C., Lo, K. K. & Cheng, A. F. (2002). Genotype spectrum of cervical human papillomavirus infection among sexually transmitted disease clinic patients in Hong Kong. J Med Virol 68, 273-277.
5. Christensen, N. D., Kreider, J. W., Cladel, N. M. & Galloway, D. A. (1990). Immunological cross-reactivity to laboratory-produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6B and HPV-16 capsid proteins. Virology 175, 1-9.
6. Christensen, N. D., Kirnbauer, R., Schiller, J. T., Ghim, S. J., Schlegel, R., Jenson, A. B. & Kreider, J. W. (1994). Human papillomavirus type-6 and type-11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205, 329-335.
7. Christensen, N. D., Dillner, J., Eklund, C., Caarter, J., Wipf, G., Reed, C., Cladel, N. & Galloway, D. A. (1996). Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223, 174-184.
8. Combita, A. L., Touze, A., Bousarghin, L., Sizaret, P. Y., Munoz, N. & Coursaget, P. (2001). Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett 204, 183-188.
9. Culp, T. D. & Christensen, N. D. (2003). Quantitative RT-PCR assay for HPV infection in cultured cells. J Virol Methods 111, 135-144.
10. Culp, T. D., Budgeon, L. R. & Christensen, N. D. (2006a). Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology 347, 147-159.
11. Culp, T. D., Budgeon, L. R., Marinkovich, M. P., Meneguzzi, G. & Christensen, N. D. (2006b). Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol 80, 8940-8950.
12. Culp, T. D., Spatz, C. M., Reed, C. A. & Christensen, N. D. (2007). Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scRv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361, 435-446.
13. Day, P. M., Lowy, D. R. & Schiller, J. T. (2003). Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307, 1-11.
14. Day, P. M., Thompson, C. D., Buck, C. B., Pang, Y. Y. S., Lowy, D. R. & Schiller, J. T. (2007). Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 81, 8784-8792.
15. Fukuchi, E., Sawaya, G. F., Chirenje, M., Magure, T., Tuveson, J., Ma, Y., Shiboski, S., Da Costa, M., Palefsky, J. & other authors (2009). Cervical human papillomavirus incidence and persistence in a cohort of HIV-negative women in Zimbabwe. Sex Transm Dis 36, 305-311.
16. Gonzalez-Losa, M. del R., Rosado-Lopez, I., Valdez-Gonzalez, N. & Puerto-Solis, M. (2004). High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. J Clin Virol 29, 202-205.
17. Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A. B., Romonowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Clemens, S. A. C. & Dubin, G. (2006). Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255.
18. Johnson, K. M., Kines, R. C., Roberts, J. N., Lowy, D. R., Schiller, J. T. & Day, P. M. (2009). Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83, 2067-2074.
19. Joyce, J. G., Tung, J. S., Przysiecki, C. T., Cook, J. C., Lehman, E. D., Sands, J. A., Jansens, K. U. & Keller, P. M. (1999). The L1 major capsid protein of human papillomavirus type 11 recombinant viruslike particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274, 5810-5822.
20. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R. & Schiller, J. T. (1993). Efficient self-assembly of human papillomavirus type-16 L1 and L1-L2 into virus-like particles. J Virol 67, 6929-6936. (Pubitemid 23343814)
21. Mejia, A. F., Culp, T. D., Cladel, N. M., Balogh, K. K., Budgeon, L. R., Buck, C. B. & Christensen, N. D. (2006). Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol 80, 12393-12397.
22. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V., Snijders, P. J. F. & Meijer, C. J. L. M. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348, 518-527. (Pubitemid 36159887)
23. Pastrana, D. V., Buck, C. B., Pang, Y. Y. S., Thompson, C. D., Castle, P. E., FitzGerald, P. C., Kjaer, S. K., Lowy, D. R. & Schiller, J. T. (2004). Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205-216.
24. Patterson, N. A., Smith, J. L. & Ozbun, M. A. (2005). Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol 79, 6838-6847.
25. Pyeon, D., Lambert, P. F. & Ahlquist, P. (2005). Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc Natl Acad Sci U S A 102, 9311-9316.
26. Rizk, R. Z., Christensen, N. D., Michael, K. M., Muller, M., Sehr, P., Waterboer, T. & Pawlita, M. (2008). Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 89, 117-129.
27. Schmiedeskamp, M. R. & Kockler, D. R. (2006). Human papillomavirus vaccines. Ann Pharmacother 40, 1344-1352.
28. Selinka, H. C., Florin, L., Patel, H. D., Freitag, K., Schmidtke, M., Makarov, V. A. & Sapp, M. (2007). Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81, 10970-10980.
29. Smith, J. L., Campos, S. K. & Ozbun, M. A. (2007). Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol 81, 9922-9931.
30. Stanley, M. A. (2006). Human papillomavirus vaccines. Rev Med Virol 16, 139-149.
31. Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C. & other authors (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6, 271-278.
32. Xi, L. F., Toure, P., Critchlow, C. W., Hawes, S. E., Dembele, A., Sow, P. S. & Kiviat, N. B. (2003). Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 103, 803-809.